Skip to main content
PMC home page
The Journal of Experimental Medicine logoLink to The Journal of Experimental Medicine
. 1988 Dec 1;168(6):2337–2347. doi: 10.1084/jem.168.6.2337

Cellularly defined minor histocompatibility antigens are differentially expressed on human hematopoietic progenitor cells

PMCID: PMC2189144  PMID: 3199071

Abstract

Previously, five CTL lines directed against minor histocompatibility (mH) antigens designated HA-1-5 have been established from peripheral blood of patients after allogeneic bone marrow transplantation (BMT), and have been characterized using population and family studies. All cell lines showed specific HLA class I-restricted lysis of PHA- stimulated peripheral blood target cells from donors positive for the particular mH antigens. After 4 h of incubation of the mH antigen HA-3- specific CTL line with bone marrow cells from HA-3+ donors, complete class I-restricted inhibition of colony growth of the hematopoietic progenitor cells was observed even at low E/T ratios, indicating that the HA-3 antigen is strongly expressed on hematopoietic stem cells. Therefore, this antigen may be a target structure in the immune- mediated rejection of the hematopoietic graft in case of incompatibility for this determinant between donor and recipient in allogeneic BMT. In contrast, incubation of bone marrow cells with the antigen-specific anti-HA-1, -2, -4, and -5 CTL lines did not result in growth inhibition of the hematopoietic progenitor cells tested. After a prolonged incubation time and using a very high E/T ratio, progenitor cells from HA-2+ or HA-5+ donors were killed to some extent by the anti- mH-specific CTL lines, although the growth inhibition observed was minor and variable. Our results show that mH antigens are differentially expressed on human hematopoietic progenitor cells. Therefore, only some of these antigens may be targets in immune- mediated rejection of the bone marrow graft.

Full Text

The Full Text of this article is available as a PDF (773.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ash R. C., Detrick D. A., Zanjani E. D. Studies of human pluripotential hemopoietic stem cells (CFU-GEMM) in vitro. Blood. 1981 Aug;58(2):309–316. [PubMed] [Google Scholar]
  2. Bortin M. M., Rimm A. A. Severe combined immunodeficiency disease. Characterization of the disease and results of transplantation. JAMA. 1977 Aug 15;238(7):591–600. [PubMed] [Google Scholar]
  3. Falkenburg J. H., Fibbe W. E., Goselink H. M., Van Rood J. J., Jansen J. Human hematopoietic progenitor cells in long-term cultures express HLA-DR antigens and lack HLA-DQ antigens. J Exp Med. 1985 Oct 1;162(4):1359–1369. doi: 10.1084/jem.162.4.1359. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Falkenburg J. H., Fibbe W. E., van der Vaart-Duinkerken N., Nichols M. E., Rubinstein P., Jansen J. Human erythroid progenitor cells express Rhesus antigens. Blood. 1985 Sep;66(3):660–663. [PubMed] [Google Scholar]
  5. Falkenburg J. H., Jansen J., van der Vaart-Duinkerken N., Veenhof W. F., Blotkamp J., Goselink H. M., Parlevliet J., van Rood J. J. Polymorphic and monomorphic HLA-DR determinants on human hematopoietic progenitor cells. Blood. 1984 May;63(5):1125–1132. [PubMed] [Google Scholar]
  6. Fischer A., Griscelli C., Blanche S., Le Deist F., Veber F., Lopez M., Delaage M., Olive D., Mawas C., Janossy G. Prevention of graft failure by an anti-HLFA-1 monoclonal antibody in HLA-mismatched bone-marrow transplantation. Lancet. 1986 Nov 8;2(8515):1058–1061. doi: 10.1016/s0140-6736(86)90465-4. [DOI] [PubMed] [Google Scholar]
  7. Fitchen J. H., Foon K. A., Cline M. J. The antigenic characteristics of hematopoietic stem cells. N Engl J Med. 1981 Jul 2;305(1):17–25. doi: 10.1056/NEJM198107023050104. [DOI] [PubMed] [Google Scholar]
  8. Glucksberg H., Storb R., Fefer A., Buckner C. D., Neiman P. E., Clift R. A., Lerner K. G., Thomas E. D. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974 Oct;18(4):295–304. doi: 10.1097/00007890-197410000-00001. [DOI] [PubMed] [Google Scholar]
  9. Goldman J. M., Apperley J. F., Jones L., Marcus R., Goolden A. W., Batchelor R., Hale G., Waldmann H., Reid C. D., Hows J. Bone marrow transplantation for patients with chronic myeloid leukemia. N Engl J Med. 1986 Jan 23;314(4):202–207. doi: 10.1056/NEJM198601233140403. [DOI] [PubMed] [Google Scholar]
  10. Goulmy E., Gratama J. W., Blokland E., Zwaan F. E., van Rood J. J. A minor transplantation antigen detected by MHC-restricted cytotoxic T lymphocytes during graft-versus-host disease. Nature. 1983 Mar 10;302(5904):159–161. doi: 10.1038/302159a0. [DOI] [PubMed] [Google Scholar]
  11. Goulmy E., Termijtelen A., Bradley B. A., van Rood J. J. Y-antigen killing by T cells of women is restricted by HLA. Nature. 1977 Apr 7;266(5602):544–545. doi: 10.1038/266544a0. [DOI] [PubMed] [Google Scholar]
  12. Iscove N. N., Senn J. S., Till J. E., McCulloch E. A. Colony formation by normal and leukemic human marrow cells in culture: effect of conditioned medium from human leukocytes. Blood. 1971 Jan;37(1):1–5. [PubMed] [Google Scholar]
  13. Korngold R., Sprent J. Lethal graft-versus-host disease after bone marrow transplantation across minor histocompatibility barriers in mice. Prevention by removing mature T cells from marrow. J Exp Med. 1978 Dec 1;148(6):1687–1698. doi: 10.1084/jem.148.6.1687. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Lundgren G., Zukoski C. F., Möller G. Differential effects of human granulocytes and lymphocytes on human fibroblasts in vitro. Clin Exp Immunol. 1968 Oct;3(8):817–836. [PMC free article] [PubMed] [Google Scholar]
  15. Madsen M., Johnsen H. E. A methodological study of E-rosette formation using AET-treated sheep red blood cells. J Immunol Methods. 1979 May 10;27(1):61–74. doi: 10.1016/0022-1759(79)90239-4. [DOI] [PubMed] [Google Scholar]
  16. Martin P. J., Hansen J. A., Storb R., Thomas E. D. Human marrow transplantation: an immunological perspective. Adv Immunol. 1987;40:379–438. doi: 10.1016/s0065-2776(08)60243-6. [DOI] [PubMed] [Google Scholar]
  17. Mitsuyasu R. T., Champlin R. E., Gale R. P., Ho W. G., Lenarsky C., Winston D., Selch M., Elashoff R., Giorgi J. V., Wells J. Treatment of donor bone marrow with monoclonal anti-T-cell antibody and complement for the prevention of graft-versus-host disease. A prospective, randomized, double-blind trial. Ann Intern Med. 1986 Jul;105(1):20–26. doi: 10.7326/0003-4819-105-1-20. [DOI] [PubMed] [Google Scholar]
  18. Neudorf S., Filipovich A., Ramsay N., Kersey J. Prevention and treatment of acute graft-versus-host disease. Semin Hematol. 1984 Apr;21(2):91–100. [PubMed] [Google Scholar]
  19. O'Reilly R. J., Brochstein J., Dinsmore R., Kirkpatrick D. Marrow transplantation for congenital disorders. Semin Hematol. 1984 Jul;21(3):188–221. [PubMed] [Google Scholar]
  20. Patterson J., Prentice H. G., Brenner M. K., Gilmore M., Janossy G., Ivory K., Skeggs D., Morgan H., Lord J., Blacklock H. A. Graft rejection following HLA matched T-lymphocyte depleted bone marrow transplantation. Br J Haematol. 1986 Jun;63(2):221–230. doi: 10.1111/j.1365-2141.1986.tb05544.x. [DOI] [PubMed] [Google Scholar]
  21. Sieff C., Bicknell D., Caine G., Robinson J., Lam G., Greaves M. F. Changes in cell surface antigen expression during hemopoietic differentiation. Blood. 1982 Sep;60(3):703–713. [PubMed] [Google Scholar]
  22. Storb R., Thomas E. D., Buckner C. D., Appelbaum F. R., Clift R. A., Deeg H. J., Doney K., Hansen J. A., Prentice R. L., Sanders J. E. Marrow transplantation for aplastic anemia. Semin Hematol. 1984 Jan;21(1):27–35. [PubMed] [Google Scholar]
  23. Thomas E. D., Buckner C. D., Clift R. A., Fefer A., Johnson F. L., Neiman P. E., Sale G. E., Sanders J. E., Singer J. W., Shulman H. Marrow transplantation for acute nonlymphoblastic leukemia in first remission. N Engl J Med. 1979 Sep 13;301(11):597–599. doi: 10.1056/NEJM197909133011109. [DOI] [PubMed] [Google Scholar]
  24. Thomas E. D., Sanders J. E., Flournoy N., Johnson F. L., Buckner C. D., Clift R. A., Fefer A., Goodell B. W., Storb R., Weiden P. L. Marrow transplantation for patients with acute lymphoblastic leukemia in remission. Blood. 1979 Aug;54(2):468–476. [PubMed] [Google Scholar]
  25. Thomas E., Storb R., Clift R. A., Fefer A., Johnson F. L., Neiman P. E., Lerner K. G., Glucksberg H., Buckner C. D. Bone-marrow transplantation (first of two parts). N Engl J Med. 1975 Apr 17;292(16):832–843. doi: 10.1056/NEJM197504172921605. [DOI] [PubMed] [Google Scholar]
  26. Voogt P. J., Fibbe W. E., Veenhof W. F., Brand A., Goulmy E., van Rood J. J., Falkenburg J. H. Cell-mediated lysis of human hematopoietic progenitor cells. Leukemia. 1987 May;1(5):427–431. [PubMed] [Google Scholar]
  27. Voogt P. J., Goulmy E., Fibbe W. E., Veenhof W. F., Brand A., Falkenburg J. H. Minor histocompatibility antigen H-Y is expressed on human hematopoietic progenitor cells. J Clin Invest. 1988 Sep;82(3):906–912. doi: 10.1172/JCI113697. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Waldmann H., Polliak A., Hale G., Or R., Cividalli G., Weiss L., Weshler Z., Samuel S., Manor D., Brautbar C. Elimination of graft-versus-host disease by in-vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (CAMPATH-1). Lancet. 1984 Sep 1;2(8401):483–486. doi: 10.1016/s0140-6736(84)92564-9. [DOI] [PubMed] [Google Scholar]

Articles from The Journal of Experimental Medicine are provided here courtesy of The Rockefeller University Press

RESOURCES